13 Panel Multi Dip Card

Thirteen-substance urine drug test dip cards available in three configurations: the standard Forensic Use Only format with integrated Fentanyl and PCP, the CLIA Waived clinical format with FEN at two sensitivity levels plus EDDP and TCA, and the advanced compliance format (SM-DOA-3135EFAD3) — the 13 panel drug test ETG variant — adding Tramadol, Ethyl Glucuronide, and three built-in adulterant detection strips for Specific Gravity, pH, and Creatinine. The 13-panel is the lowest tier where Fentanyl is a standard built-in analyte across all configurations — not an optional add-on. Searching for a 13 panel drug test near me? 12 Panel Now ships same-day wholesale anywhere in the US before 3:00 PM EST, free shipping on bulk orders. As the manufacturer of the Serenity brand drug testing product line, 12 Panel Now produces all 13-panel dip cards to the same quality control standards applied across the full product range.

The table below shows the complete 13 panel drug test substances list for each configuration, with cutoffs and detection windows.

Shop 13 Panel Drug Test Dip Card with TRA, ETG, FEN and Adulterants (SKU SM-DOA-3135EFAD3) — from $1.89 | 13 Panel Standard FUO with FEN (SM-DOA-2135FUO) — from $1.29 | CLIA Waived 13 Panel (SM-DOA-2135CLIA) — from $1.29

What Does a 13 Panel Drug Test Test For?

A 13 panel urine drug test dip card screens for thirteen substances in a single dip, with the defining characteristic of this tier being that Fentanyl is integrated as a standard strip across all configurations — not an optional add-on as it is at lower panel counts. At 12 Panel Now, the 13 Panel Drug Test Dip Card is available in three configurations — the Standard FUO format with FEN and PCP, the CLIA Waived format with FEN at 20 ng/mL and at 1 ng/mL plus EDDP and TCA, and the advanced compliance format (SM-DOA-3135EFAD3) adding Tramadol (TRA), Ethyl Glucuronide (ETG), and three adulterant detection strips. The HHS Federal Register mandate of January 2025 adding fentanyl to authorized federal testing panels effective July 7, 2025 makes the 13-panel the minimum configuration that meets the federal substance authorization standard in a single dip card. The SAMHSA Drug-Free Workplace Program confirms that fentanyl detection requires a dedicated FEN immunoassay strip and cannot be inferred from any standard OPI or opiate analyte, making the 13-panel’s integrated FEN strip the critical upgrade from the 12-panel baseline.

How Does the 13 Panel Differ From the 12 Panel Drug Test?

The 13 panel vs 12 panel drug test comparison comes down to one question: is fentanyl in the panel? The 12-panel dip card covers twelve substances including AMP, BAR, BUP, BZO, COC, MDMA, MET, MTD, OPI, OXY, PCP or TCA, and THC — but does not include a dedicated FEN strip in its standard configuration. The 13-panel takes that same twelve-substance baseline and adds fentanyl detection as the integrated thirteenth analyte. For programs that have been running a 12-panel and asking whether they are compliant with the post-July 2025 federal fentanyl authorization standard, the answer is that they need a 13-panel or higher configuration that includes a dedicated FEN strip. According to the Quest Diagnostics 2025 Drug Testing Index, fentanyl positivity in random workforce testing reached 1.13% in 2024, with 60% of fentanyl-positive specimens also positive for another substance — making the 12-to-13-panel upgrade operationally significant for any program concerned about opioid detection completeness.

Does Tramadol Show Up on a Drug Test?

A tramadol drug test requires a dedicated TRA strip — tramadol does not show up on a standard opiate drug test — it requires its own dedicated TRA drug test strip, and the 13 Panel Drug Test Dip Card with TRA, ETG, FEN and Adulterants (SM-DOA-3135EFAD3) is the lowest panel count in the 12 Panel Now dip card lineup where tramadol receives a dedicated analyte at 100 ng/mL. The question “does tramadol show on opiate drug test” is one of the most searched drug testing questions in the US, and the answer is consistently misunderstood: tramadol is a synthetic opioid with a distinct chemical structure that does not trigger the OPI (opiate/morphine) immunoassay antibody at clinically encountered concentrations. A person taking therapeutic doses of tramadol (Ultram, ConZip) will consistently test negative on the OPI strip, regardless of how many opioid analytes are on the panel, unless TRA is specifically included. The PubMed research on tramadol immunoassay cross-reactivity documents that tramadol demonstrates low cross-reactivity with standard opiate immunoassays and requires a dedicated tramadol-specific antibody system for reliable urine detection. For pain management programs that prescribe tramadol and need to verify patient compliance, a panel without a dedicated TRA strip is providing no useful information about the prescribed medication. For employers in safety-sensitive industries where tramadol impairment is a documented concern, the standard OPI strip provides no protection against tramadol-impaired workers.

What Is TRA on a Drug Test and What Does Tramadol Detect?

TRA stands for Tramadol, a centrally acting synthetic opioid analgesic prescribed for moderate to moderately severe pain under brand names including Ultram, ConZip, and generic tramadol, detected on the 13-panel dip card at a 100 ng/mL cutoff with a detection window of 1 to 4 days in most adults. Tramadol works by binding to opioid receptors and inhibiting serotonin and norepinephrine reuptake simultaneously — a dual mechanism that distinguishes it pharmacologically from classical opioids like morphine and oxycodone. This dual mechanism is also why tramadol is not detected by opioid immunoassay strips: the OPI antibody is calibrated to morphine and morphine-related metabolites, and tramadol’s molecular structure does not produce the cross-reactivity needed to trigger a positive OPI result. The TRA strip at 100 ng/mL uses tramadol-specific antibodies that react to tramadol and its primary active metabolite O-desmethyltramadol (M1) at concentrations consistent with therapeutic use. Because tramadol is one of the most commonly prescribed opioids in the US for outpatient pain management — with tens of millions of prescriptions written annually — its absence from standard drug testing panels creates a significant detection gap for programs that need to monitor opioid analgesic use comprehensively. Programs that need both OXY compliance monitoring and TRA compliance monitoring in a single dip should use the 13 Panel TRA+ETG+FEN+ADLTX dip card.

What Is ADLTX on a Drug Test and How Does Adulteration Detection Work?

ADLTX stands for Adulterants Detection — and understanding what is ADLTX on a drug test is important because it is not a drug panel but a specimen integrity check — three specimen validity strips (Specific Gravity, pH, and Creatinine) built into the SM-DOA-3135EFAD3 dip card that assess whether the urine specimen is physiologically consistent with a genuine voided sample before any drug result is read. A urine drug test adulterants check runs simultaneously with the drug panel and identifies common tampering methods. Specific Gravity detects overly dilute specimens (values below 1.003) and hyperdilute specimens (values below 1.001) that suggest the donor consumed excessive fluids immediately before the test to dilute drug metabolite concentrations below detectable thresholds. pH detects specimens outside the normal 4.5 to 9.0 range that suggest addition of acidic or alkaline adulterants such as bleach, vinegar, or drain cleaner to the specimen after collection. Creatinine detects specimens with creatinine concentrations below 2 mg/dL, which — combined with a low specific gravity — is the definitive indicator of specimen substitution or extreme dilution. An adulteration drug test using ADLTX strips catches these tampering methods at the point of collection, before any drug result is interpreted, allowing the collecting official to flag the specimen as invalid and require a fresh observed collection rather than reporting a false negative on the drug panel itself. The SAMHSA Mandatory Guidelines specify specimen validity criteria that directly align with the three ADLTX parameters measured by the SM-DOA-3135EFAD3’s adulterant strips.

How to Detect a Diluted Urine Drug Test Sample

Dilute specimens are the most common form of test manipulation in supervised drug testing programs. A donor who drinks 1 to 2 liters of water in the 1 to 2 hours before a urine drug test can reduce THC, amphetamine, and other metabolite concentrations by 50 to 75 percent, often enough to bring concentrations below the immunoassay cutoff threshold and produce a false negative result. Without ADLTX strips, a collecting official reading only the drug test panel has no way to distinguish a genuine negative result from a negative result produced by dilution. The Specific Gravity strip on the SM-DOA-3135EFAD3 provides an immediate validity check: a specific gravity below 1.003 at the point of collection flags the specimen as dilute regardless of the drug panel result and triggers a repeat collection protocol. The Creatinine strip provides a parallel validity marker — creatinine below 20 mg/dL is defined as dilute under SAMHSA criteria, and creatinine below 2 mg/dL is defined as substituted. Programs using the tramadol 13 panel drug test — the 13-panel dip card with ADLTX — eliminate the most common specimen manipulation method without any additional equipment, additional strips, or additional cost beyond the per-card price. Probation programs, drug court monitoring, and correctional facilities where specimen manipulation is a documented ongoing concern benefit most from the ADLTX-integrated format.

Does the 13 Panel Drug Test Detect Fentanyl?

Yes — the 13 panel drug test fentanyl coverage is standard: a dedicated FEN strip at 20 ng/mL across all three configurations, making it the lowest panel count in the 12 Panel Now dip card lineup where fentanyl detection is standard across every available format. The FEN strip at 20 ng/mL uses fentanyl-specific antibodies that react to fentanyl and its metabolites at concentrations consistent with recent exposure. This threshold reflects fentanyl’s extreme pharmacological potency — the drug produces physiological effects at nanogram-scale blood concentrations, meaning even low urine concentrations are clinically significant. The HHS Federal Register notice of January 2025 mandating fentanyl addition to authorized federal testing panels effective July 7, 2025 establishes the regulatory basis for why the 13-panel’s integrated FEN strip represents the current federal policy standard for comprehensive opioid detection. The CLIA Waived 13-panel configuration (SM-DOA-2135CLIA) adds an additional FEN strip at 1 ng/mL alongside the standard 20 ng/mL strip — providing ultra-sensitive fentanyl detection for clinical settings managing patients with potential fentanyl exposure where even trace quantities are medically significant. The ADLTX+TRA+ETG configuration includes FEN/20 alongside the tramadol and alcohol metabolite strips, making it the most analytically complete single dip card in the 13-panel format available from 12 Panel Now.

Is the 13 Panel Drug Test CLIA Waived?

Yes — the CLIA Waived 13 panel drug test configuration (SM-DOA-2135CLIA) is CLIA Waived and FDA 510(k) cleared for use in clinical settings by minimally trained operators without a laboratory certification requirement. The 13 panel drug test CLIA waived variant covering AMP/BAR/BUP/BZO/COC/FEN/MDMA/MET/MTD/OPI/OXY/TCA/THC with EDDP and FEN at 1 ng/mL is the appropriate choice for physician offices, occupational medicine clinics, addiction treatment programs, and any setting operating under CLIA jurisdiction that needs fentanyl detection alongside the standard clinical monitoring baseline. The Forensic Use Only configurations (SM-DOA-2135FUO and SM-DOA-3135EFAD3) are appropriate for probation, corrections, law enforcement, and compliance settings that do not fall under CLIA jurisdiction. Programs uncertain about which classification applies to their setting should review the CLIA Waived verification guide at 12 Panel Now. The CDC’s waived test classification guidance provides the regulatory framework for confirming that a device used in a clinical setting has the appropriate CLIA Waived designation.

Who Uses the 13 Panel Drug Test Dip Card?

The 13 panel drug test dip card is used by pain management clinics, MAT programs, opioid treatment programs, occupational medicine departments, probation offices, correctional facilities, drug courts, sober living homes, and any program that needs the full 12-panel baseline plus dedicated fentanyl detection in a single dip — and by advanced compliance programs that additionally need tramadol monitoring, alcohol metabolite detection, and specimen validity checking. Pain management clinics that prescribe tramadol as an adjunct or alternative analgesic to opioids use the TRA+ETG+FEN+ADLTX configuration because it simultaneously confirms tramadol compliance (TRA), screens for concurrent illicit opioid and fentanyl use (OPI, OXY, FEN), checks for BZO and BAR co-use risk, and validates the specimen has not been diluted or substituted (ADLTX). Methadone treatment programs and buprenorphine clinics use the 13-panel CLIA Waived configuration because the integrated FEN strip brings their point-of-care screening into compliance with the post-July 2025 federal standard while maintaining the CLIA Waived status required for clinical administration. Probation programs and drug courts with documented tramadol misuse patterns in their supervised population use the TRA configuration alongside ADLTX to prevent the two most common forms of compliance avoidance: tramadol substitution for illicit opioids and specimen dilution.

Is the 13 Panel Drug Test Right for Workplace Drug Testing?

For non-DOT employers, the 13-panel dip card is the first tier that meets the post-July 2025 federal fentanyl authorization standard in a single integrated device. DOT-regulated employers remain bound by the federally mandated 5-panel, but non-DOT employers who adopted a 12-panel as their standard and have not yet added a FEN analyte should evaluate the 13-panel as their updated baseline. The Standard FUO format (SM-DOA-2135FUO) at $1.29 provides the cost-efficient upgrade from the 12-panel to fentanyl-inclusive coverage with minimal additional cost per test. The TRA+ETG+FEN+ADLTX format is appropriate for employer programs in industries where tramadol prescription use is prevalent in the workforce, alcohol abstinence compliance is a condition of employment, and specimen validity documentation is a chain-of-custody requirement. The OSHA Drug-Free Workplace guidelines confirm that panel configuration for non-regulated employers should reflect the specific substance risk profile of the workforce. For DOT-regulated employers, the 13-panel dip card is appropriate for supplemental non-safety-sensitive screening outside the regulated program.

What Does the 13 Panel Drug Test NOT Detect?

The 13 panel drug test dip card does not detect kratom, gabapentin, K2 or synthetic cannabinoids, xylazine, ketamine, MDPV, psilocybin, LSD, delta-8 THC, norfentanyl (unless the CLIA Waived NFYL configuration is selected), or any substance beyond its thirteen dedicated strips and ADLTX validity markers. The norfentanyl metabolite of fentanyl persists in urine longer than fentanyl itself — up to 96 hours versus 72 hours for fentanyl — but is only detected by the CLIA Waived variant that includes the NFYL strip alongside the standard FEN/20 strip. Programs that need norfentanyl detection alongside fentanyl for extended detection windows should select the CLIA Waived NFYL configuration or evaluate the 15 through 19 panel dip card formats that include NFYL as a standard strip. Kratom detection requires a dedicated KRA strip first available in 16-panel and higher configurations. Gabapentin requires a GAB strip available in 15-panel and higher formats. For programs whose populations use any of these substances alongside the 13-panel baseline, the dip card format guide at 12 Panel Now provides a full comparison of available analyte configurations across the 13 through 19 panel tier.

Which 13 Panel Configuration Is Right for Your Program?

Choose the Standard FUO (SM-DOA-2135FUO) at $1.29 if your program needs fentanyl and PCP alongside the full 12-panel baseline in a Forensic Use Only format for probation, corrections, or workplace settings. Choose the CLIA Waived (SM-DOA-2135CLIA) at $1.29 if your program operates in a clinical setting that requires CLIA Waived status alongside fentanyl detection at both 20 ng/mL and 1 ng/mL sensitivity. Choose the 13 panel drug test with adulterants (SM-DOA-3135EFAD3) at $1.89 if your program needs tramadol compliance monitoring, alcohol abstinence verification via ETG, and specimen validity checking alongside fentanyl detection in a single card. The three configurations serve distinct clinical and compliance populations. The Standard FUO is the lowest-cost entry to fentanyl-integrated 13-panel screening. The CLIA Waived format provides the dual FEN sensitivity needed in healthcare settings where patients may be prescribed fentanyl at therapeutic doses. The ADLTX format addresses three distinct compliance gaps — tramadol detection, alcohol abstinence monitoring via ETG, and specimen integrity validation — that no other single dip card in the lineup covers simultaneously at this price point. Contact the 12 Panel Now wholesale team at 561-897-9238 or [email protected] to discuss which configuration is the right match for your specific program requirements.

How Accurate Is the 13 Panel Drug Test Dip Card?

All three 13-panel configurations deliver 99% accuracy across all strips when administered correctly. The most sensitive analyte on the panel is BUP at 10 ng/mL, followed by the FEN strip at 20 ng/mL in the standard and ADLTX configurations. Both benefit from strict adherence to the 10 to 15 second dip time and the 5-minute read window — do not read after 10 minutes. The ADLTX validity strips on the SM-DOA-3135EFAD3 are read simultaneously with the drug panel strips at 5 minutes, not separately. For each of the thirteen drug strips, two colored bands across both the control (C) and test (T) regions indicate a negative result. A single band only in the control region is a presumptive positive. No control band indicates an invalid test requiring a fresh specimen and new card. Any presumptive positive on any strip must be confirmed by GC-MS or LC-MS/MS laboratory analysis before any employment, clinical, or legal action is taken. The SAMHSA Drug-Free Workplace FAQ confirms that laboratory confirmation is mandatory before any consequential action on a positive rapid immunoassay result.

13 Panel Drug Test Dip Card vs 13 Panel Drug Test Cup

Both the dip card and the 13 panel drug test cup detect the same thirteen substances at equivalent immunoassay accuracy. The dip card formats starting from $1.29 are the lower-cost choice for high-volume monitoring programs. The cup format provides integrated collection, built-in temperature validation, and tamper-evident sealed design for chain-of-custody settings. The 13 panel drug test cup at 12 Panel Now is available in multiple configurations including the standard cup, the ETG+FEN configuration, and the ADLTX cup format — all with the no-drip lid, built-in temperature strip, and photocopy-compatible result windows. For rehabilitation programs and sober living homes running high-frequency testing where direct staff oversight of collection is standard, the dip card’s lower per-test cost provides meaningful savings at scale without sacrificing substance coverage. For compliance settings with legal accountability requirements, the cup’s specimen integrity features are the appropriate choice. Browse the full comparison at the 13 panel drug test category at 12 Panel Now.

Buying 13 Panel Drug Test Dip Cards in Bulk

At 12 Panel Now, the 13 panel drug test bulk and wholesale pricing is available from $1.29 per test for the Standard FUO and CLIA Waived configurations and from $1.89 for the TRA+ETG+FEN+ADLTX format, with 13 panel drug test wholesale orders shipping same-day before 3:00 PM EST and free shipping on qualifying bulk orders. As the US-based manufacturer of the Serenity brand drug testing product line, 12 Panel Now carries over 15 million products in stock at all times with no backorders. Each card is individually foil-sealed with an 18 to 24 month shelf life. Store between 36 and 86 degrees Fahrenheit away from direct sunlight and humidity. The FEN strip at 20 ng/mL and BUP strip at 10 ng/mL are the most temperature-sensitive analytes on the card — temperature-controlled bulk storage is recommended for programs ordering high volumes. Mixed SKU bulk orders combining any 13-panel dip card configuration with supplemental fentanyl strips or single-panel add-ons can be placed in a single order. Send us a competitor rate sheet and we beat it by 10% guaranteed. OEM, private label, and custom panel configurations are available. Contact 561-897-9238 or [email protected].

13 Panel Drug Test Dip Cards at 12 Panel Now (Serenity Drug Test / Slash Medical), 801 N Congress Ave, Boynton Beach FL 33426. Manufacturer of the Serenity brand drug testing product line. Key products: SM-DOA-2135FUO (Standard FUO, AMP/BAR/BUP/BZO/COC/FEN/MDMA/MET/MTD/OPI/OXY/PCP/THC, from $1.29); SM-DOA-2135CLIA (CLIA Waived, adds TCA/1000, FEN/1 and EDDP, from $1.29); SM-DOA-3135EFAD3 (TRA/ETG/FEN/ADLTX FUO, AMP/BUP/BZO/COC/ETG/FEN/MDMA/MET/MTD/OPI/OXY/TRA/THC + 3 Adulterants, from $1.89). Regulatory references: SAMHSA Mandatory Guidelines 2025. HHS fentanyl authorization effective July 7, 2025. SAMHSA specimen validity criteria (Specific Gravity, pH, Creatinine). Quest Diagnostics 2025 Drug Testing Index. PubMed tramadol immunoassay cross-reactivity research. CDC CLIA Waived test classification guidance. OSHA Drug-Free Workplace guidelines